nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Hypocalcaemia—Epirubicin—liver cancer	0.00376	0.00376	CcSEcCtD
Ibandronate—Angioedema—Sorafenib—liver cancer	0.00372	0.00372	CcSEcCtD
Ibandronate—Ulcer—Epirubicin—liver cancer	0.00364	0.00364	CcSEcCtD
Ibandronate—Cardiovascular disorder—Doxorubicin—liver cancer	0.00362	0.00362	CcSEcCtD
Ibandronate—Creatinine increased—Epirubicin—liver cancer	0.00361	0.00361	CcSEcCtD
Ibandronate—Bone pain—Epirubicin—liver cancer	0.00359	0.00359	CcSEcCtD
Ibandronate—Inflammation—Epirubicin—liver cancer	0.00355	0.00355	CcSEcCtD
Ibandronate—Hypertension—Sorafenib—liver cancer	0.00351	0.00351	CcSEcCtD
Ibandronate—Arthropathy—Doxorubicin—liver cancer	0.0035	0.0035	CcSEcCtD
Ibandronate—Musculoskeletal pain—Epirubicin—liver cancer	0.00348	0.00348	CcSEcCtD
Ibandronate—Hypocalcaemia—Doxorubicin—liver cancer	0.00348	0.00348	CcSEcCtD
Ibandronate—Arthralgia—Sorafenib—liver cancer	0.00346	0.00346	CcSEcCtD
Ibandronate—Myalgia—Sorafenib—liver cancer	0.00346	0.00346	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00344	0.00344	CcSEcCtD
Ibandronate—Vaginal inflammation—Epirubicin—liver cancer	0.00344	0.00344	CcSEcCtD
Ibandronate—Injection site reaction—Epirubicin—liver cancer	0.00342	0.00342	CcSEcCtD
Ibandronate—Dry mouth—Sorafenib—liver cancer	0.00339	0.00339	CcSEcCtD
Ibandronate—Ulcer—Doxorubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Ibandronate—Cystitis noninfective—Epirubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Ibandronate—Creatinine increased—Doxorubicin—liver cancer	0.00334	0.00334	CcSEcCtD
Ibandronate—Influenza like illness—Epirubicin—liver cancer	0.00334	0.00334	CcSEcCtD
Ibandronate—Bone pain—Doxorubicin—liver cancer	0.00332	0.00332	CcSEcCtD
Ibandronate—Cystitis—Epirubicin—liver cancer	0.00332	0.00332	CcSEcCtD
Ibandronate—Anaphylactic shock—Sorafenib—liver cancer	0.00332	0.00332	CcSEcCtD
Ibandronate—Infection—Sorafenib—liver cancer	0.0033	0.0033	CcSEcCtD
Ibandronate—Candida infection—Epirubicin—liver cancer	0.00328	0.00328	CcSEcCtD
Ibandronate—Inflammation—Doxorubicin—liver cancer	0.00328	0.00328	CcSEcCtD
Ibandronate—Shock—Sorafenib—liver cancer	0.00327	0.00327	CcSEcCtD
Ibandronate—Nervous system disorder—Sorafenib—liver cancer	0.00326	0.00326	CcSEcCtD
Ibandronate—Vaginal infection—Epirubicin—liver cancer	0.00325	0.00325	CcSEcCtD
Ibandronate—Skin disorder—Sorafenib—liver cancer	0.00322	0.00322	CcSEcCtD
Ibandronate—Musculoskeletal pain—Doxorubicin—liver cancer	0.00322	0.00322	CcSEcCtD
Ibandronate—Vaginal inflammation—Doxorubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Ibandronate—Injection site reaction—Doxorubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Ibandronate—Oesophagitis—Epirubicin—liver cancer	0.00314	0.00314	CcSEcCtD
Ibandronate—Bladder pain—Epirubicin—liver cancer	0.00311	0.00311	CcSEcCtD
Ibandronate—Mouth ulceration—Epirubicin—liver cancer	0.00311	0.00311	CcSEcCtD
Ibandronate—Ecchymosis—Epirubicin—liver cancer	0.00311	0.00311	CcSEcCtD
Ibandronate—Cystitis noninfective—Doxorubicin—liver cancer	0.00311	0.00311	CcSEcCtD
Ibandronate—Influenza like illness—Doxorubicin—liver cancer	0.00309	0.00309	CcSEcCtD
Ibandronate—Cystitis—Doxorubicin—liver cancer	0.00307	0.00307	CcSEcCtD
Ibandronate—Pulmonary oedema—Epirubicin—liver cancer	0.00306	0.00306	CcSEcCtD
Ibandronate—Candida infection—Doxorubicin—liver cancer	0.00304	0.00304	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00302	0.00302	CcSEcCtD
Ibandronate—Hypertonia—Epirubicin—liver cancer	0.00301	0.00301	CcSEcCtD
Ibandronate—Vaginal infection—Doxorubicin—liver cancer	0.003	0.003	CcSEcCtD
Ibandronate—Dyspepsia—Sorafenib—liver cancer	0.00292	0.00292	CcSEcCtD
Ibandronate—Oesophagitis—Doxorubicin—liver cancer	0.00291	0.00291	CcSEcCtD
Ibandronate—Decreased appetite—Sorafenib—liver cancer	0.00289	0.00289	CcSEcCtD
Ibandronate—Bladder pain—Doxorubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Ibandronate—Ecchymosis—Doxorubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Ibandronate—Mouth ulceration—Doxorubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Sorafenib—liver cancer	0.00287	0.00287	CcSEcCtD
Ibandronate—Fatigue—Sorafenib—liver cancer	0.00286	0.00286	CcSEcCtD
Ibandronate—Constipation—Sorafenib—liver cancer	0.00284	0.00284	CcSEcCtD
Ibandronate—Pain—Sorafenib—liver cancer	0.00284	0.00284	CcSEcCtD
Ibandronate—Pulmonary oedema—Doxorubicin—liver cancer	0.00283	0.00283	CcSEcCtD
Ibandronate—Hypertonia—Doxorubicin—liver cancer	0.00279	0.00279	CcSEcCtD
Ibandronate—Gastrointestinal pain—Sorafenib—liver cancer	0.00271	0.00271	CcSEcCtD
Ibandronate—Renal failure acute—Epirubicin—liver cancer	0.0027	0.0027	CcSEcCtD
Ibandronate—Urticaria—Sorafenib—liver cancer	0.00264	0.00264	CcSEcCtD
Ibandronate—Body temperature increased—Sorafenib—liver cancer	0.00262	0.00262	CcSEcCtD
Ibandronate—Abdominal pain—Sorafenib—liver cancer	0.00262	0.00262	CcSEcCtD
Ibandronate—Renal impairment—Epirubicin—liver cancer	0.00262	0.00262	CcSEcCtD
Ibandronate—Renal failure acute—Doxorubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Ibandronate—Osteoarthritis—Epirubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Ibandronate—Pain in extremity—Epirubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Ibandronate—Migraine—Epirubicin—liver cancer	0.00246	0.00246	CcSEcCtD
Ibandronate—Hypersensitivity—Sorafenib—liver cancer	0.00245	0.00245	CcSEcCtD
Ibandronate—Renal impairment—Doxorubicin—liver cancer	0.00243	0.00243	CcSEcCtD
Ibandronate—Face oedema—Epirubicin—liver cancer	0.00241	0.00241	CcSEcCtD
Ibandronate—Asthenia—Sorafenib—liver cancer	0.00238	0.00238	CcSEcCtD
Ibandronate—Pruritus—Sorafenib—liver cancer	0.00235	0.00235	CcSEcCtD
Ibandronate—Blood creatinine increased—Epirubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Ibandronate—Pain in extremity—Doxorubicin—liver cancer	0.00231	0.00231	CcSEcCtD
Ibandronate—Osteoarthritis—Doxorubicin—liver cancer	0.00231	0.00231	CcSEcCtD
Ibandronate—Abdominal pain upper—Epirubicin—liver cancer	0.00228	0.00228	CcSEcCtD
Ibandronate—Migraine—Doxorubicin—liver cancer	0.00227	0.00227	CcSEcCtD
Ibandronate—Diarrhoea—Sorafenib—liver cancer	0.00227	0.00227	CcSEcCtD
Ibandronate—Breast disorder—Epirubicin—liver cancer	0.00226	0.00226	CcSEcCtD
Ibandronate—Nasopharyngitis—Epirubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Ibandronate—Face oedema—Doxorubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Ibandronate—Gastritis—Epirubicin—liver cancer	0.00221	0.00221	CcSEcCtD
Ibandronate—Dizziness—Sorafenib—liver cancer	0.0022	0.0022	CcSEcCtD
Ibandronate—Blood creatinine increased—Doxorubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Asthma—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Influenza—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Dysphagia—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Vomiting—Sorafenib—liver cancer	0.00211	0.00211	CcSEcCtD
Ibandronate—Abdominal pain upper—Doxorubicin—liver cancer	0.00211	0.00211	CcSEcCtD
Ibandronate—Rash—Sorafenib—liver cancer	0.00209	0.00209	CcSEcCtD
Ibandronate—Dermatitis—Sorafenib—liver cancer	0.00209	0.00209	CcSEcCtD
Ibandronate—Breast disorder—Doxorubicin—liver cancer	0.00209	0.00209	CcSEcCtD
Ibandronate—Headache—Sorafenib—liver cancer	0.00208	0.00208	CcSEcCtD
Ibandronate—Bronchitis—Epirubicin—liver cancer	0.00208	0.00208	CcSEcCtD
Ibandronate—Nasopharyngitis—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Ibandronate—Gastritis—Doxorubicin—liver cancer	0.00204	0.00204	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Epirubicin—liver cancer	0.00201	0.00201	CcSEcCtD
Ibandronate—Influenza—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Ibandronate—Asthma—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Ibandronate—Dysphagia—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Ibandronate—Nausea—Sorafenib—liver cancer	0.00197	0.00197	CcSEcCtD
Ibandronate—Weight decreased—Epirubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Ibandronate—Pneumonia—Epirubicin—liver cancer	0.00194	0.00194	CcSEcCtD
Ibandronate—Infestation—Epirubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Ibandronate—Infestation NOS—Epirubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Ibandronate—Renal failure—Epirubicin—liver cancer	0.00189	0.00189	CcSEcCtD
Ibandronate—Stomatitis—Epirubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Ibandronate—Urinary tract infection—Epirubicin—liver cancer	0.00187	0.00187	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00186	0.00186	CcSEcCtD
Ibandronate—Sweating—Epirubicin—liver cancer	0.00184	0.00184	CcSEcCtD
Ibandronate—Hepatobiliary disease—Epirubicin—liver cancer	0.00182	0.00182	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—liver cancer	0.00181	0.00181	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—liver cancer	0.00179	0.00179	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—liver cancer	0.00175	0.00175	CcSEcCtD
Ibandronate—Haemoglobin—Epirubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Ibandronate—Haemorrhage—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Ibandronate—Pharyngitis—Epirubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Ibandronate—Urinary tract disorder—Epirubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Ibandronate—Oedema peripheral—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Ibandronate—Connective tissue disorder—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Ibandronate—Urethral disorder—Epirubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—liver cancer	0.00168	0.00168	CcSEcCtD
Ibandronate—Eye disorder—Epirubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Ibandronate—Cardiac disorder—Epirubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—liver cancer	0.00159	0.00159	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Angiopathy—Epirubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Immune system disorder—Epirubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Ibandronate—Mediastinal disorder—Epirubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Ibandronate—Chills—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Ibandronate—Alopecia—Epirubicin—liver cancer	0.00153	0.00153	CcSEcCtD
Ibandronate—Mental disorder—Epirubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Ibandronate—Erythema—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Ibandronate—Malnutrition—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—liver cancer	0.00149	0.00149	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Ibandronate—Flatulence—Epirubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Ibandronate—Dysgeusia—Epirubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Ibandronate—Back pain—Epirubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Ibandronate—Muscle spasms—Epirubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Chills—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—liver cancer	0.0014	0.0014	CcSEcCtD
Ibandronate—Ill-defined disorder—Epirubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Anaemia—Epirubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Ibandronate—Malaise—Epirubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Ibandronate—Vertigo—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—liver cancer	0.00134	0.00134	CcSEcCtD
Ibandronate—Palpitations—Epirubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Ibandronate—Hypertension—Epirubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Arthralgia—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Chest pain—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Myalgia—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Anxiety—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Ibandronate—Discomfort—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Ibandronate—Dry mouth—Epirubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Ibandronate—Anaphylactic shock—Epirubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Ibandronate—Infection—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Ibandronate—Shock—Epirubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Ibandronate—Nervous system disorder—Epirubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Skin disorder—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Ibandronate—Hyperhidrosis—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Ibandronate—Infection—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Ibandronate—Shock—Doxorubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Ibandronate—Insomnia—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Paraesthesia—Epirubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Dyspepsia—Epirubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Ibandronate—Decreased appetite—Epirubicin—liver cancer	0.00107	0.00107	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Ibandronate—Fatigue—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Ibandronate—Pain—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Ibandronate—Constipation—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Ibandronate—Feeling abnormal—Epirubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Ibandronate—Gastrointestinal pain—Epirubicin—liver cancer	0.001	0.001	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—liver cancer	0.000999	0.000999	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—liver cancer	0.000987	0.000987	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00098	0.00098	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—liver cancer	0.000979	0.000979	CcSEcCtD
Ibandronate—Urticaria—Epirubicin—liver cancer	0.000975	0.000975	CcSEcCtD
Ibandronate—Pain—Doxorubicin—liver cancer	0.000971	0.000971	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—liver cancer	0.000971	0.000971	CcSEcCtD
Ibandronate—Abdominal pain—Epirubicin—liver cancer	0.00097	0.00097	CcSEcCtD
Ibandronate—Body temperature increased—Epirubicin—liver cancer	0.00097	0.00097	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—liver cancer	0.000936	0.000936	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—liver cancer	0.000928	0.000928	CcSEcCtD
Ibandronate—Hypersensitivity—Epirubicin—liver cancer	0.000904	0.000904	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—liver cancer	0.000902	0.000902	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—liver cancer	0.000898	0.000898	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—liver cancer	0.000898	0.000898	CcSEcCtD
Ibandronate—Asthenia—Epirubicin—liver cancer	0.00088	0.00088	CcSEcCtD
Ibandronate—Pruritus—Epirubicin—liver cancer	0.000868	0.000868	CcSEcCtD
Ibandronate—Diarrhoea—Epirubicin—liver cancer	0.00084	0.00084	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—liver cancer	0.000836	0.000836	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—liver cancer	0.000815	0.000815	CcSEcCtD
Ibandronate—Dizziness—Epirubicin—liver cancer	0.000811	0.000811	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—liver cancer	0.000803	0.000803	CcSEcCtD
Ibandronate—Vomiting—Epirubicin—liver cancer	0.00078	0.00078	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—liver cancer	0.000777	0.000777	CcSEcCtD
Ibandronate—Rash—Epirubicin—liver cancer	0.000774	0.000774	CcSEcCtD
Ibandronate—Dermatitis—Epirubicin—liver cancer	0.000773	0.000773	CcSEcCtD
Ibandronate—Headache—Epirubicin—liver cancer	0.000769	0.000769	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—liver cancer	0.000751	0.000751	CcSEcCtD
Ibandronate—Nausea—Epirubicin—liver cancer	0.000729	0.000729	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—liver cancer	0.000722	0.000722	CcSEcCtD
Ibandronate—Rash—Doxorubicin—liver cancer	0.000716	0.000716	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—liver cancer	0.000715	0.000715	CcSEcCtD
Ibandronate—Headache—Doxorubicin—liver cancer	0.000711	0.000711	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—liver cancer	0.000674	0.000674	CcSEcCtD
